EYPT EyePoint Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 01 April 2020 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update

   - Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities - - Reorganization of Commercial Operations to Align with Focused Approach -

2. 05 March 2020 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress

   – Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 – – Net product revenues of $7.9 million in Q4 2019 and $16.8 million for full year 2019 – – Q4 2019 customer demand for DEXYCU and YUTIQ

3. 02 March 2020 EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®

   WATERTOWN, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced

4. 27 February 2020 EyePoint Pharmaceuticals Announces Fourth Quarter and Full-Year 2019 Financial Results Release Date and Conference Call Information

   WATERTOWN, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report

5. 21 February 2020 EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock

   WATERTOWN, Mass., Feb. 21, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced

6. 20 February 2020 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

   WATERTOWN, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced

7. 18 February 2020 EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®

   WATERTOWN, Mass. and NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and

8. 03 February 2020 EyePoint Pharmaceuticals Signs Exclusive License Agreement with Equinox Science to Develop Tyrosine Kinase Inhibitor Vorolanib for the Treatment of Wet AMD, Diabetic Retinopathy and Retinal Vein Occlusion

    – EYP-1901 combines vorolanib with EyePoint's bioerodible Durasert™ technology as a six-month sustained release intravitreal therapeutic program to potentially reduce injection frequency of currently available

9. 27 January 2020 EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan

   WATERTOWN, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension

10. 23 January 2020 EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues

    - Q4 2019 total revenues are estimated to be between $7.5 - $8.2 million and full-year 2019 total revenues are estimated to be between $19.3 - $20.0 million - - Q4 2019 net product revenues are estimated to be between

11. 04 December 2019 EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU® Within One of the Largest Integrated Delivery Systems in the U.S.

    WATERTOWN, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

12. 19 November 2019 EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility

    WATERTOWN, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

13. 14 November 2019 EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

    WATERTOWN, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

14. 07 November 2019 EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress

    – U.S. commercial launch trajectory for DEXYCU® and YUTIQ® gains momentum with strong customer order growth over Q2 – – DEXYCU customer orders increased 207% over Q2 with repeat customers representing 74% of order

15. 04 November 2019 EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule

    - DEXYCU and YUTIQ now available across the VA and on Federal Supply Schedule to benefit U.S. veterans and other government employees - WATERTOWN, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals,

16. 01 November 2019 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®

    WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

17. 24 October 2019 EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information

    WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will

18. 02 October 2019 EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect

    WATERTOWN, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products,

19. 27 September 2019 EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

    WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

20. 26 September 2019 EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today

21. 09 September 2019 EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting

    WATERTOWN, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today